Reversal of bioprosthetic aortic valve thrombrosis using rivaroxaban- a case report

Harish Sharma, Vincenzo Vetrugno, Peter Ludman

Research output: Contribution to journalArticlepeer-review

127 Downloads (Pure)


Background: Bioprosthetic valve thrombosis (BPVT) is a rare but recognized complication causing valve dysfunction. In subacute valve thrombosis, systemic oral anticoagulation is recommended. However, there is little data comparing the efficacy of warfarin and novel oral anticoagulant (NOAC) therapy in this setting.

Case Summary: A patient developed subacute BPVT 11 years post-implantation. The patient was initially treated with warfarin for a period of 6 months, with limited effect. Following replacement of warfarin with rivaroxaban, there was significant reversal of the BPVT, as represented by a reduction in transaortic maximal velocity (Vmax) from 4.1 to 3 m/s over 7 months.

Discussion: Systemic oral anticoagulation can be an effective treatment for subacute valve thrombosis. Guidelines currently recommend warfarin as first line but NOACs can be considered in such patients and may be more effective than warfarin. Randomized controlled trials are required to further establish the optimal anticoagulation for patients with subacute BPVT.
Original languageEnglish
Article number87
Number of pages5
JournalFrontiers in cardiovascular medicine
Publication statusPublished - 27 May 2020


  • rivaroxaban
  • valve thrombosis
  • thrombosis reversal
  • Bioprosthetic aortic valve
  • NOAC


Dive into the research topics of 'Reversal of bioprosthetic aortic valve thrombrosis using rivaroxaban- a case report'. Together they form a unique fingerprint.

Cite this